Krill Oil for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Krill Oil for Health & Longevity

Created on 06/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A marine supplement supplying omega-3 fats largely bound to phospholipids (the molecules cell membranes are made of), plus the antioxidant astaxanthin. Best-supported effects: lowering blood triglycerides, modestly improving cholesterol, raising omega-3 status, and easing mild knee joint symptoms. Benefits are real but modest, resting on small short studies. Shellfish allergy is an absolute barrier. (Full Review)

Protocol

Standard Dose
1–3 g/day
Delivers ~200–600 mg combined EPA+DHA; lipid-focused regimens have used up to 3–4 g/day.
Best Time of Day
With largest fatty meal
Improves absorption and reduces reflux; no strong morning vs. evening rationale.
Single vs. Split Dosing
Single daily dose
Adequate due to slow membrane turnover; split only to reduce GI effects at higher doses.
Time to effect
Lipid & Omega-3 Index
4–12 weeks
Plateau typically around 8–12 weeks of consistent daily use.
Joint Symptoms
1–6 months
Joint-symptom improvements emerged over roughly 1–6 months in trials.
Acute Effect
None expected
No acute effect should be expected from krill oil.

Benefits

Contraindications
  • Crustacean-shellfish allergy (absolute)
    •
Key Interactions
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin)
  • Over-the-counter NSAIDs (ibuprofen, naproxen, aspirin)
  • Other omega-3 supplements (fish oil, algal oil, cod liver oil) and high-dose vitamin E
  • Blood-pressure–lowering agents
  • Orlistat
    •

Risk & Side Effects

  • High:
  • Medium: Shellfish allergy reactions
    •
  • Low: Gastrointestinal upset; bleeding risk and platelet effects
    •
  • Speculative: Oxidation and rancidity exposure; contaminant accumulation
    •

Monitoring

Marker Target Why
Omega-3 Index 8–12% Reflects EPA+DHA in cell membranes; the primary biomarker of marine omega-3 status.
Triglycerides <90 mg/dL The lipid most responsive to omega-3s; the main quantitative success marker.
LDL Cholesterol <100 mg/dL (lower if high CVD risk) Krill oil may modestly lower LDL; tracks overall lipid response.
HDL Cholesterol >50 mg/dL (women), >40 mg/dL (men) May rise modestly with krill oil; part of complete lipid assessment.
High-sensitivity CRP (hs-CRP) <1.0 mg/L General marker of body-wide inflammation that omega-3s may reduce.

Cadence: Baseline, then ~12 weeks after starting, then every 6–12 months for long-term use; closer follow-up with dose changes or anticoagulants.

Qualitative Assessment

  • Joint comfort and stiffness — particularly morning stiffness and knee function
  • Digestive tolerance — absence of fishy reflux or GI upset
  • Energy and general well-being — subjective vitality
  • Cognitive clarity and mood — subjective focus and mood stability
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.